Calibration Free Supersaturation Assessment and Control for the Development and Optimization of Crystallization...(ATR-FTIR peak height values. The present...)

Date:10/9/2009

ATR-FTIR peak height values. The presented strategy demonstrates how qualitative supersaturation trajectories can be controlled to a specific set point and in turn ensure particle dimension and quality are not jeopardized in the tech transfer and scale-up of these processes.

The knowledge gained when coupled with in situ particle dimension information significantly increase process understanding and as a result minimal experimentation is required to output a desirable crystallization process.

The webinar presenter, Mark Barrett, received his Ph.D. from University College Dublin (UCD) in Ireland, where he also studied Chemical Engineering. His thesis work focused on crystallization development and scale-up. Previously, Mark worked for Schering-Plough as a Process Development Engineer. Mark is now a Senior Research and Development Engineer at the Solid State Pharmaceutical Cluster (SSPC), based in Ireland. Mark Barrett also presented the Optimization and Scale-up of Anti-Solvent Addition Crystallizations From Lab to Pilot Plant Webinar Series.

# # #

Read the full story at http://www.prweb.com/releases/crystallization/supersaturation/prweb3013864.htm.

'/>"/>

Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
2. Hidden diversity in key environmental cleanup microbes found by systems biology assessment
3. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
6. Assessment of safety and efficacy of human embryonic stem cell therapy
7. Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients
8. PDHI Launches Short Form of Its ConXus Profile Health Assessment
9. The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment
10. New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema
11. 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis